Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A

Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Cell Mol Med
Autori principali: Xu, Qingqing, Liu, Xiaofei, Zhu, Shiqin, Hu, Xuelei, Niu, Huanmin, Zhang, Xiulei, Zhu, Deyu, Nesa, Effat Un, Tian, Keli, Yuan, Huiqing
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5824406/
https://ncbi.nlm.nih.gov/pubmed/29327812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13475
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi